TRCT
PBE icon

Tower Research Capital (TRC)’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Tower Research Capital (TRC)’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-399
Closed -$17K – 3244
2017
Q1 		$17K Buy
+399
New +$16.7K ﹤0.01% 1399

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CAS
Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Tower Research Capital (TRC)'s PBE Position: Q2 2017 in Review

Tower Research Capital (TRC) sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2017, closing a stake of 399 shares — an estimated $17K sold.

Tower Research Capital (TRC) first reported a position in PBE in Q1 2017 and held it in 1 quarter. The position peaked at $17K in Q1 2017. 64 funds tracked by Wall St. Rank hold PBE as of Q2 2017.

  • Tower Research Capital (TRC) reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 399 Invesco Biotechnology & Genome ETF shares in Q2 2017, an estimated $17K.
  • Tower Research Capital (TRC) first reported a position in Invesco Biotechnology & Genome ETF in Q1 2017 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Invesco Biotechnology & Genome ETF position peaked at $17K in Q1 2017.
  • 64 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2017, filed 15 Aug 2017.